PTGX241220C12500
- 18.60
- 0.000.00%
Protagonist Therapeutics Newsroom
Clear Street Launches Healthcare & Biotechnology Equity Research
BTIG Upgrades Protagonist Therapeutics(PTGX.US) to Buy Rating, Maintains Target Price $67
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58
Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising Rusfertide Data and Strategic Takeda Partnership
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $50
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58
J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Protagonist Therapeutics (PTGX)
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
Protagonist Therapeutics Initiated at Outperform by BMO Capital
Protagonist Therapeutics Price Target Announced at $62.00/Share by BMO Capital
Protagonist Therapeutics Analyst Ratings
Goldman Sachs Initiates Protagonist Therapeutics(PTGX.US) With Hold Rating, Announces Target Price $47
Protagonist Therapeutics Initiated With a Neutral at Goldman Sachs
BMO Capital Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $62
Buy Rating Affirmed for Protagonist Therapeutics: Innovative Peptide Platform and Promising Pipeline Drive Growth Prospects
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $58
Protagonist Therapeutics Price Target Raised to $58 From $43 at JMP Securities
Yun Zhong, PhD, Joins Wedbush Securities as Senior Vice President, Equity Research, Biotechnology
Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?